Updated:
Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories is a contract research organization founded in 1957 in Tokyo, Japan. It offers nonclinical research, translational...
Shin Nippon Biomedical Laboratories
Shin Nippon Biomedical Laboratories is a contract research organization founded in 1957 in Tokyo, Japan. It offers nonclinical research, translational research, and medipolis business services. The company is based in Tokyo.
General information
Firm type
Asset Manager
Year founded
1957
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Additional offices
San Francisco, US · Boston, US
Sector focus
Frequently asked questions
What does Shin Nippon Biomedical Laboratories actually do?
SNBL operates three units anchored by Japan's first contract research organization. The CRO division runs nonclinical and clinical trials for drug developers. A translational research arm identifies academic biotech assets and applies in-house nasal-delivery technology to advance them. The company also maintains hospitality, energy, and aquaculture projects under a social-profit umbrella.
How does the firm deploy capital?
Capital allocation flows through the translational research arm, which licenses or co-develops early-stage therapeutic programs. SNBL does not disclose a separate fund structure or AUM. Deployment amounts are not published.
Is SNBL a family office or a public company?
SNBL is a listed Japanese corporation operating in the pharmaceutical-services sector. No family ownership or family-office label has been disclosed. The firm grew out of a laboratory founded in 1957 and became Japan's pioneer CRO.
Where are SNBL's offices located?
The headquarters are in Tokyo, Japan. The company also maintains offices in San Francisco and Boston, United States, supporting a trans-Pacific operational model for nonclinical and translational work.
What is the firm's proprietary intranasal technology?
SNBL has developed a drug-delivery platform designed for nasal administration of therapeutics. The company uses this technology internally to reformulate and advance early-stage drug candidates, especially within its translational research collaborations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: